Heron Therapeutics interim report shows every reported income line in the red, with the half-year profit-to-loss swing as the binding signal

Bottom line

HERON THERAPEUTICS, INC. /DE/ (the company identified by HRTX and 0000818033) filed an interim report under 10-Q for period-ended-2026-06-30, posted under 0001193125-26-341301. On the reported income-statement lines this section is built on — diluted earnings per share, net income attributable to the parent, and operating income — every window the filing discloses is in the red. For the three-month reporting period (the three months ended June 30, 2026), diluted earnings per share came in at -$0.03 per diluted share USD/SHARES, worse than the prior-year the three months ended June 30, 2025 figure of -$0.02 per diluted share USD/SHARES, and net income attributable to the parent landed at -$5,489,000 USD against -$2,381,000 USD a year earlier. Operating income followed the same shape, with -$2,044,000 USD for the current quarter versus -$1,637,000 USD in the prior-year quarter. The year-to-date window tells the sharper story: for the six months ended June 30, 2026, diluted EPS of -$0.07 per diluted share USD/SHARES sits against $0 per diluted share USD/SHARES the year before, net income attributable to the parent of -$13,600,000 USD is a swing from the prior-year $254,000 USD profit, and operating income of -$6,809,000 USD reverses the prior-year operating profit of $1,517,000 USD. The same transition is visible at the bottom line, where year-to-date diluted earnings moved from a zero-EPS reading a year ago to a loss in the current window. Operating-income and net-income movements for the year-to-date period follow that same profit-to-loss reversal, while the quarterly comparisons remain loss-to-loss.

Management explanation: the filing's narrative covers trademark protection, forward-looking statements, commercial positioning of the Products portfolio, the CrossLink Network arrangement, intellectual-property scope, going-concern liquidity, the Nasdaq Capital Market minimum bid price, and ongoing clinical and regulatory work. None of that narrative directly reconciles the income-statement reversals described above, and the source scope offered to this section does not include segment-level breakdowns, cost-of-revenue detail, or share-count dilution schedules.

Analyst inference: isolated to the income statement, all four windows above sit in the red and the year-to-date windows show the largest deterioration relative to the prior year, consistent with a company still in the loss-making phase of commercial ramp-up across its Products portfolio. Cross-checking against a peer or industry benchmark for these lines is not possible from the filing evidence.

Counter-evidence: the filing's perimeter here is income-statement only; no operating-cash-flow figure is supplied for this section, so a cash-versus-earnings counterpoint cannot be grounded in catalog facts.

Unknowns: The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Financial performance

- **Year-over-year (six-month window):** Over the longer reporting window, parent-level net result moved from a profit in the prior-year period to a loss in the current period, based on Net Income (Loss) Attributable to Parent for the six-month year-to-date period versus its prior-year comparative. The same profit-to-loss transition is observable on Operating Income (Loss) for the matching window, and on diluted Earnings Per Share, where the prior-year half-year figure was at break-even and the current half-year figure is a loss. - **Year-over-year (three-month window):** Both Net Income (Loss) Attributable to Parent and Operating Income (Loss) for the current quarter registered losses, against losses in the prior-year quarter as well, with the loss reported in each line on the three-month basis deeper than the prior-year quarter's loss. Diluted Earnings Per Share similarly shows a loss in the current quarter and a loss in the prior-year quarter, with the current-period loss larger than the comparative loss. Note Note 8 discusses Long-Term Debt and Convertible Notes and is cited in connection with the basis of preparation of the financial statements, though it does not quantify the swing. - **Quarter-over-quarter (current three-month window vs. six-month window):** Each reported loss line — parent net result, operating result, and diluted EPS — appears smaller in magnitude on the quarter alone than on the year-to-date half-year basis, indicating that the first half absorbed the heavier portion of the deterioration. No quarter-vs-quarter_prior_year directive applies to half-year-only items, and no quarter-only cash-flow or capex lines are authorized in this section. - **Guidance and forward-looking posture:** The forward-looking statements paragraph frames the outlook entirely in terms of risks — regulatory, commercial, manufacturing, geopolitical, financing, and personnel — without offering quantified targets, period guidance, or numeric milestones. The company explicitly states that any forward-looking statements reflect views as of the filing date and disclaims an obligation to update them, except as required by law. Accordingly, no numeric revenue, margin, earnings, or cash guidance is asserted in this filing. - **Accounting context:** The financial statements are presented on the basis described in the cited note Note 2, covering Current Assets and the cash and short-term investment positions that anchor the balance sheet framing. The same Note 8 reference confirms that Long-Term Debt and Convertible Notes are addressed within the notes that frame these statements, though the section does not quantify the debt service impact on the year-over-year swing.

- **Counter-evidence / reconciliation note:** Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

- **Unknowns:** The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Operating drivers and segments

the filing presents Heron Therapeutics as a single operating entity built around its branded acute-care and oncology-support products — ZYNRELEF, APONVIE, CINVANTI and SUSTOL — supported by the Biochronomer technology platform, with no separately reported business segments in the cited note disclosures. Because the company reports on an aggregated basis, segment-level revenue, segment-level operating income and segment-level margins are not disclosed in the evidence available for this section, so any split between the marketed Products, any pipeline candidates and the Biochronomer platform cannot be derived from the filing itself. Operating performance is therefore observed only at the consolidated level: Operating Income (Loss) was -$6,809,000 USD for the six months ended June 30, 2026, a loss, compared with Operating Income (Loss) of $1,517,000 USD for the six months ended June 30, 2025, a profit. For the three-month reporting period, Operating Income (Loss) was -$2,044,000 USD for the three months ended June 30, 2026, a loss, compared with Operating Income (Loss) of -$1,637,000 USD for the three months ended June 30, 2025, a loss. The two authorized transitions are a profit-to-loss shift at the half-year level and a loss-to-loss continuation at the quarter level, with both windows carrying an authorized direction of decrease, so the operating-line deterioration is observed both versus the prior-year six months and versus the prior-year quarter.

The cited note text directs readers to the Long-Term Debt and Convertible Notes discussion in Note 8 and the balance-sheet presentation in Note 2, but the filing evidence does not contain a management commentary block that attributes the operating loss to a specific revenue line, cost category, inventory adjustment, royalty event, litigation accrual or commercial milestone. The forward-looking-statements section frames Heron's commercial focus on ZYNRELEF, APONVIE, CINVANTI and SUSTOL, the CrossLink Network co-promotion arrangement, ongoing litigation, intellectual-property scope, listing standards on the Nasdaq Capital Market, going-concern considerations without additional funding, and postmarketing requirements, none of which is tied by the filing to the change in Operating Income (Loss) for the periods reported here. As a result, the reader-facing explanation for the move from prior-year profit to current-year loss at the half-year level, and for the wider quarter-level loss, cannot be sourced from a stated driver inside the catalog: The filing evidence does not attribute this change to any single cause.. No peer or industry comparison is supplied, so the magnitude of the deterioration also cannot be benchmarked against sector trends: The filing evidence contains no peer or industry comparison.. For independent verification, the same pattern of widening operating loss has been observed at other specialty pharma issuers, as captured in Perspective Therapeutics widens loss on every reported line in the latest interim filing, which readers can compare against Heron's two reported windows.

Cash flow and capital

- The year-to-date cash flow profile in this interim filing from HERON THERAPEUTICS, INC. /DE/ (HRTX) for the six months ended the six months ended June 30, 2026 shows operating activities consuming cash, while financing activities supplied cash, the typical pattern for a pre-profit specialty pharmaceutical issuer funding a working-capital deficit and debt-service requirements. Net Cash Provided by (Used in) Operating Activities for the six months ended June 30, 2026 was -$3,753,000 USD, an authorised increase relative to the prior-year comparative of -$19,738,000 USD, meaning the cash burn narrowed rather than widened even as the parent-level income line moved from profit to loss.

- Net Cash Provided by (Used in) Investing Activities swung to a use of cash for the six months ended June 30, 2026 of -$4,204,000 USD, an authorised decrease relative to the prior-year comparative of $9,607,000 USD. The shift from a positive investing line to a negative one over the longer reporting window is the principal year-over-year movement on the cash flow statement. - Within investing outflows, Payments to Acquire Property, Plant, and Equipment for the six months ended June 30, 2026 were $529,000 USD, an authorised increase relative to the prior-year comparative of $317,000 USD, so capital spending rose even as the broader investing line turned negative on a year-over-year basis.

- Net Cash Provided by (Used in) Financing Activities for the six months ended June 30, 2026 was $31,000 USD, an authorised decrease relative to the prior-year comparative of $845,000 USD, indicating that external funding was still positive in absolute terms but smaller than a year earlier. - The narrative accompanying the statements ties the cash, cash-equivalents and short-term investments balances to a control agreement established under the working-capital facility, with disclosure in the cited note on long-term debt and convertible notes (Note 8), and presents short-term investments as available-for-sale securities classified as current because management expects to be able to liquidate them within the next several months if liquidity needs arise.

- The balance sheet date of the balance sheet date of June 30, 2026 carries cash and cash equivalents of $20,721,000 USD alongside accounts receivable, after the allowance for credit loss, of $89,571,000 USD and accounts payable of $11,641,000 USD, reflecting the working-capital footprint that the cash flow statement is funding. - Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

- The filing evidence does not attribute this change to any single cause. - The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison.

- For capital-allocation context beyond the cash flow statement, readers can compare this profile against peers such as the Perspective Therapeutics widens loss on every reported line in the latest interim filing insight, which examines a similar interim disclosure.

Peer and historical context

- The year-to-date operating result shifted from a profit to a loss on the longer reporting window, mirroring the move at the parent net-income line over the same window, while both lines remained in loss on the shorter window. - Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window, leaving the cash-flow line and the earnings line pointing in opposite directions. Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

On the six-month year-to-date view, the operating cash outflow narrowed compared with the prior-year window, so a reader looking only at cash usage would not see the deterioration that the parent-level loss implies; the divergence between the cash-flow line and the earnings line is the counter-signal here. The filing evidence does not attribute this change to any single cause.

Scenario analysis

The conditional read for HERON THERAPEUTICS, INC. /DE/ on this period-ended-2026-06-30 10-Q filing under accession 0001193125-26-341301 is framed almost entirely by the parent-level earnings line, because that is the single dimension where the catalog carries an authorized profit-to-loss transition in the longer window and an authorized loss-to-loss continuation in the quarter. The base, upside and downside paths below therefore start from the same reported Net Income (Loss) Attributable to Parent values and ask what would have to be true about the surrounding statements — cash generation, financing, balance-sheet posture — for each path to hold.

Reported Net Income (Loss) Attributable to Parent moved from a profit in the prior-year six-month window to a loss in the current six-month window, and the current quarter remained a loss against a prior-year quarter that was also a loss, so the base case is that the parent-level loss is the central reported fact for both reported windows. - Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window, so the base case treats liquidity from operations as supportive rather than as evidence of an accelerating cash burn, while still flagging that the headline earnings line is the binding constraint. - The base case carries forward the going-concern context implied by the cited note on long-term debt and convertible notes, recognizing that refinancing and conversion mechanics are a real sensitivity even though the exact terms are not restated here.

The upside path would require the parent-level loss on the quarter line to narrow materially against the prior-year quarter loss, and the longer-window loss to compress back toward breakeven, without the operating-cash improvement reversing. - It would also require a constructive reading of the balance-sheet posture in the cited balance-sheet note, with cash, cash equivalents and short-term investments providing a runway that comfortably clears the working-capital needs implied by receivables and inventory discipline described in the credit-risk and inventory policies. - In an upside frame, the same operating-cash strengthening becomes evidence that the underlying business is funding its own working capital despite the reported loss, which is a qualitative distinction rather than a numeric re-cast.

The downside path assumes the parent-level loss deepens on both reported windows relative to the prior-year comparisons, while operating cash flow deteriorates from the current positive reading, so the supportive divergence between cash and earnings would no longer be available as an offset. - It would also assume stress on the long-term debt and convertible notes posture flagged in the cited note, raising the probability that the credit-risk and concentration disclosures in the customer channel start to bind in a more concrete way. - Under that combination, the loss-to-loss quarter transition and the profit-to-loss longer-window transition both stand as the headline risk, with the operating-cash improvement treated as a temporary rather than a structural feature.

Across all three paths, the qualitative reader takeaway is that the earnings transition is the binding reported signal, while cash, balance-sheet and financing context is the swing factor. The filing evidence does not attribute this change to any single cause. Peer and industry comparators are not part of the record on this filing, so cross-sectional context is left out of each scenario. The filing evidence contains no peer or industry comparison. Segment-level detail is similarly absent from the catalog for the dimensions the scenarios lean on, so the paths stay at the consolidated level. The filing evidence does not disclose segment-level detail for this dimension.

Risks and what to watch

- Reported facts: for the three-month reporting period, Net Income (Loss) Attributable to Parent printed as a loss of -$5,489,000 USD, compared with a smaller loss of -$2,381,000 USD in the prior-year comparative; for the six-month year-to-date period, the parent-level result swung from a profit of $254,000 USD in the prior-year comparative to a loss of -$13,600,000 USD. The longer window also shows Net Cash Provided by (Used in) Operating Activities improving on a smaller absolute outflow, Net Cash Provided by (Used in) Investing Activities swinging from an inflow to an outflow, and Net Cash Provided by (Used in) Financing Activities contracting, alongside higher Payments to Acquire Property, Plant, and Equipment.

Earnings Per Share, Diluted collapsed from a non-negative prior-year figure to a loss in the half-year window, and Accretion (Amortization) of Discounts and Premiums on Investments eased. - Management explanations: the narrative accompanying the financial statements describes the lease accounting policy, including ROU asset and lease liability recognition, the use of the incremental borrowing rate when an implicit rate is not provided, and the revenue-recognition policy under the cited ASC topic for sales to customers who resell to end users, with transfer of control tied to delivery.

Inventory wording notes that adverse market conditions could force write-downs recorded as cost of product sales; the cited note covers long-term debt and convertible notes, while the cited note addresses balance-sheet line items. - Analyst inference: the divergence between the reported parent-level earnings trajectory and the operating cash trajectory is notable; readers should weigh the Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

when interpreting headline losses. Higher capital expenditure against a financing-outflow contraction is also worth tracking, The filing evidence does not attribute this change to any single cause.. Segment-level commentary is The filing evidence does not disclose segment-level detail for this dimension.

for this period, and peer benchmarking is The filing evidence contains no peer or industry comparison.. - Counter-evidence: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. — operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window, which complicates a reading that the headline loss reflects across-the-board deterioration.

- Unknowns: the filing evidence does not attribute the period-over-period movements to any single cause, so drivers for the half-year transition from profit to loss, the investing-activity flip, and the capex increase are flagged as The filing evidence does not attribute this change to any single cause.. The narrative does not quantify the inventory write-down exposure beyond noting that adverse market conditions could trigger it. - Metrics to watch next period: parent-level Net Income (Loss) Attributable to Parent for both windows, the operating cash trajectory, the financing-versus-investing balance, capex run-rate, lease-related balances, and any disclosure under the cited note and the cited note.

For broader context on widening-loss dynamics in interim filings, readers can compare with Perspective Therapeutics widens loss on every reported line in the latest interim filing.